AbbVie Inc http://www.globalpost.com/taxonomy/term/27548/all en UPDATE 4-Abbott results bode well for spun-off AbbVie http://www.globalpost.com/dispatch/news/thomson-reuters/130123/update-3-abbott-results-bode-well-spun-abbvie <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>* Abbott 2013 profit forecast slightly above Street view</p> <p>* Humira sales growth a good sign for AbbVie</p> <p>* Abbott shares slip; AbbVie shares rise 3.8 percent</p> <p>By Ransdell Pierson</p> <p>Jan 23 (Reuters) - AbbVie Inc, the new branded pharmaceuticals company spun off by Abbott Laboratories Inc , is off to a good start, judging by fourth-quarter sales of arthritis drug Humira and other products in its medicine chest.</p> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130123/update-3-abbott-results-bode-well-spun-abbvie" target="_blank">read more</a></p> Abbott Laboratories Abbott Laboratories Inc AbbVie Inc Entertainment Health Hospitality Medicine Pharmacology Thomson Reuters Wed, 23 Jan 2013 19:30:55 +0000 Thomson Reuters 5738461 at http://www.globalpost.com AbbVie's hepatitis C treatment helps 96 pct of patients in trial http://www.globalpost.com/dispatch/news/thomson-reuters/131118/abbvies-hepatitis-c-treatment-helps-96-percent-patients-trial <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>(Reuters) - AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks.</p> <p>AbbVie shares rose 3 percent. Shares of Enanta Pharmaceuticals Inc, which collaborates with AbbVie on one of the drugs included in the treatment, rose 4 percent.</p> <p>The trial is being watched closely because of the potential of the treatment, 3D regimen, to eliminate the need for the injectable drug interferon, which can have debilitating side effects.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/131118/abbvies-hepatitis-c-treatment-helps-96-percent-patients-trial" target="_blank">read more</a></p> AbbVie Inc Antivirals Medicine Pharmacology Technology Thomson Reuters Mon, 18 Nov 2013 15:34:10 +0000 Thomson Reuters 5992474 at http://www.globalpost.com AbbVie says 96 percent patients in oral hepatitis C study show improvement http://www.globalpost.com/dispatch/news/thomson-reuters/131210/abbvie-says-96-percent-patients-oral-hepatitis-c-study-show-imp <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>(Reuters) - AbbVie Inc said a late-stage trial of its experimental hepatitis C therapy showed 96 percent of the patients who had previously failed to respond to treatment had no detectable levels of the virus in the blood after 12 weeks.</p> <p>The late-stage trial, named Sapphire-II, tested AbbVie's oral hepatitis C treatment in 394 patients who had failed to respond to an earlier treatment with a combination of standard hepatitis C drugs - pegylated interferon and ribavirin.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/131210/abbvie-says-96-percent-patients-oral-hepatitis-c-study-show-imp" target="_blank">read more</a></p> AbbVie Inc Antivirals Medicine Pharmacology Thomson Reuters Tue, 10 Dec 2013 14:02:27 +0000 Thomson Reuters 6015580 at http://www.globalpost.com AbbVie sees 2014 approval of hepatitis drugs, shares rise http://www.globalpost.com/dispatch/news/thomson-reuters/140131/abbvie-sees-2014-approval-hepatitis-drugs-shares-rise <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Ransdell Pierson</p> <p>(Reuters) - AbbVie Inc issued a cautious 2014 profit forecast, but said it expects U.S. approval this year for its potentially lucrative new all-oral treatment for hepatitis C, sending its shares up 3.4 percent.</p> <p>The company, before releasing fourth quarter earnings on Friday, released favorable data from four additional Phase III studies of its experimental treatment for the liver disease. AbbVie previously had said it expected approval of the treatment in early 2015.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2014.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/140131/abbvie-sees-2014-approval-hepatitis-drugs-shares-rise" target="_blank">read more</a></p> AbbVie Inc Biology Health Medicine Thomson Reuters Fri, 31 Jan 2014 16:34:17 +0000 Thomson Reuters 6058311 at http://www.globalpost.com Takeover target Shire makes the case to remain a standalone company after AbbVie overture http://www.globalpost.com/dispatch/news/the-canadian-press/140623/takeover-target-shire-makes-the-case-remain-standalone-compa <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> The Canadian Press </div> </div> </div> <!--paging_filter--><p>LONDON - Takeover target Shire on Monday highlighted its potential as a standalone drugmaker, offering investors a rosy projection of its earnings potential that it believes is not reflected in the acquisition proposal made by U.S.-based rival AbbVie.</p> <p>Chief Executive Flemming Ornskov told analysts that Shire PLC should remain independent, and that it expects to more than double its 2013 annual product sales to $10 billion by 2020.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.globalpost.com/terms-use#cp">Copyright 2014 Canadian Press.</a></p> <p>All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.</p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/the-canadian-press/140623/takeover-target-shire-makes-the-case-remain-standalone-compa" target="_blank">read more</a></p> AbbVie Inc Mergers and acquisitions Shire PLC The Canadian Press Mon, 23 Jun 2014 16:20:11 +0000 The Canadian Press 6184807 at http://www.globalpost.com Shire confirms in talks with AbbVie on takeover bid http://www.globalpost.com/dispatch/news/thomson-reuters/140711/shire-confirms-talks-abbvie-takeover-bid <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>(Reuters) - Shire Plc on Friday confirmed it has held a meeting with U.S. drugmaker AbbVie Inc to discuss AbbVie's takeover bid for the Dublin-based maker of drugs for rare diseases.</p> <p>Shire, in a release, did not provide any additional information about the meeting, saying it would provide a further update "when appropriate." It added there can be no certainty that any firm offer will be made nor as to the terms of any such offer.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2014.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/140711/shire-confirms-talks-abbvie-takeover-bid" target="_blank">read more</a></p> AbbVie Inc Monoclonal antibodies Shire PLC Thomson Reuters Fri, 11 Jul 2014 20:51:47 +0000 Thomson Reuters 6202833 at http://www.globalpost.com Shire, AbbVie to announce $53 billion merger by Friday: sources http://www.globalpost.com/dispatch/news/thomson-reuters/140717/shire-abbvie-announce-53-billion-merger-friday-sources <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Olivia Oran and Soyoung Kim</p> <p>(Reuters) - Shire Plc &lt;SHP.L&gt; and U.S. drugmaker Abbvie Inc &lt;ABBV.N&gt; plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday.</p> <p>Dublin-based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer. </p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2014.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/140717/shire-abbvie-announce-53-billion-merger-friday-sources" target="_blank">read more</a></p> AbbVie Inc AstraZeneca Business Monoclonal antibodies Shire PLC Thomson Reuters Thu, 17 Jul 2014 17:38:48 +0000 Thomson Reuters 6207766 at http://www.globalpost.com U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal http://www.globalpost.com/dispatch/news/thomson-reuters/140718/abbvie-succeeds-shire-courtship-53-billion-deal <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Paul Sandle</p> <p>LONDON (Reuters) - U.S. drugmaker AbbVie Inc bought Dublin-based Shire Plc on Friday in a 32 billion pound ($54.7 billion) deal that will allow it to slash its tax bill by relocating to Britain.</p> <p>The London-listed company, which makes expensive medicines to treat rare diseases, fought off four earlier bids from AbbVie until the U.S. firm raised its price to 52.48 pounds per share - made up of 24.44 pounds in cash and 0.8960 new AbbVie shares.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2014.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/140718/abbvie-succeeds-shire-courtship-53-billion-deal" target="_blank">read more</a></p> AbbVie Inc Business Investment Investment banks Shire PLC Technology Thomson Reuters Fri, 18 Jul 2014 13:18:28 +0000 Thomson Reuters 6208467 at http://www.globalpost.com